Concepedia

Author

István Májer

Pharmerit (Netherlands)

Also Known As

I M Majer, I Majer, I Májer, I. M. Majer, I. Majer, I. Májer, I.M. Majer, ISTVAN MAJER, Istvan M. Majer, Istvan Majer

85

Publications

859

Citations

15

H-Index

20

Concepts

All Affiliations

Pharmerit (Netherlands)Erasmus MCErasmus University RotterdamNational Institute for Public Health and the Environment
IM

About

István Májer is an author at Pharmerit (Netherlands) specializing in health policy, public health, and health economics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Policy

3

3

136

2

Medicine

2

2

102

3

Public Health

2

2

56

4

Health Sciences

1

1

34

5

Orthopaedics

1

1

80

István Májer

×

15

Publications

685

Citations

14

H-Index

YearCitations

Socioeconomic inequalities in life and health expectancies around official retirement age in 10 Western-European countries

István Májer, W J Nusselder, Johan P. Mackenbach,

Journal of Epidemiology & Community Health

2010

157

Mortality Risk Associated With Disability: A Population-Based Record Linkage Study

István Májer, Wilma J. Nusselder, Johan P. Mackenbach,

American Journal of Public Health

2011

121

Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999–2003

Márta Péntek, Csaba Horváth, I Boncz,

Osteoporosis International

2007

80

Cost-Effectiveness of a Chemoprophylactic Intervention with Single Dose Rifampicin in Contacts of New Leprosy Patients

Willemijn J. Idema, István Májer, David Pahan,

PLoS neglected tropical diseases

2010

46

Modeling and Forecasting Health Expectancy: Theoretical Framework and Application

István Májer, Ralph Stevens, Wilma J. Nusselder,

Demography

2012

44

Life Expectancy and Life Expectancy With Disability of Normal Weight, Overweight, and Obese Smokers and Nonsmokers in Europe

István Májer, Wilma J. Nusselder, Johan P. Mackenbach,

Obesity

2011

36

Which Factors Enhance Positive Drug Reimbursement Recommendation in Scotland? A Retrospective Analysis 2006–2013

M. Charokopou, István Májer, Johan de Raad,

Value in Health

2015

34

Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis

Thomas Wilke, S. Mueller, Sze Chim Lee,

BMC Musculoskeletal Disorders

2017

32

Forecasting Lifetime and Aggregate Long-term Care Spending

Claudine A. M. de Meijer, István Májer, Marc Koopmanschap,

Medical Care

2012

24

Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States

Andrzej Jakubowiak, Ivan Houisse, István Májer,

Expert Review of Hematology

2017

23

Page 1